Vaccinia Virus anticorps (Biotin)

N° du produit ABIN955498

Cet anticorps Lapin Polyclonal détecte spécifiquement Vaccinia Virus dans EIA et IHC (p). Il présente une réactivité avec des échantillons de Vaccinia Virus (VACV).

Aperçu rapide pour Vaccinia Virus anticorps (Biotin) (ABIN955498)

Antigène: Vaccinia Virus (VACV) (Vaccina Virus (VACV))

Reactivité: Vaccinia Virus (VACV)

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Vaccinia Virus est conjugé à/à la Biotin

Application: Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-Vaccinia Virus anticorps (Biotin)

Purification: Protein A Chromatography

Immunogène: Lister Strain (mixture of virions and ICPs)

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 4-5 mg/mL (OD280 nm, E0.1% = 1.4)

Buffer: 0.01 M PBS pH 7.2 containing 0.09 % Sodium Azide as preservative. Contains no stabilizing proteins.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Stockage commentaire: Store the antibody undiluted at -20 °C only.

Détails sur Vaccinia Virus

Antigène: Vaccinia Virus (VACV) (Vaccina Virus (VACV))

Autre désignation: Vaccinia Virus

Classe de substances: Virus

Sujet: Vaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process.